AZN Astrazeneca
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Company profile
Ticker
AZN, AZNCF
Exchange
Website
CEO
Pascal Soriot
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ZENECA GROUP PLC
SEC CIK
Corporate docs
AZN stock data
()
News
Johnson & Johnson Pulls Application For Accelerated Approval Of COVID-19 Shot In India: Report
2 Aug 21
AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years
2 Aug 21
AstraZeneca Announced- Saphnelo Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
2 Aug 21
Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report
1 Aug 21
Cashing COVID-19 Vaccine - AstraZeneca Or Pfizer
29 Jul 21
Press releases
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
27 Jul 21
Thinking about trading options or stock in F5 Networks, Waste Management, AstraZeneca, Advanced Micro Devices, or Apple?
27 Jul 21
Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria
26 Jul 21
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
23 Jul 21
Thinking about trading options or stock in Carnival Corp, AstraZeneca, Moderna, Las Vegas Sands, or Texas Instruments?
22 Jul 21
Calendar
15 Feb 21
2 Aug 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Astrazeneca earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Mar 21 | Astrazeneca | Common Stock | Dispose U | Yes | No | 53 | 14,650,334 | 776.47M | 0 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
2.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 3.43B |
| Total shares | 68.53M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Wellington Management | 68.53M | $3.43B |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
6th grade Avg
|
|
New words:
AbbVie, absence, acute, adjuvant, admission, Agent, Alexion, antitrust, Arimidex, arranged, arrangement, Atacand, attestation, beneficial, Bidco, Branch, bridge, Casodex, charter, Chase, circular, climate, consummate, consummated, consummation, contemplated, contract, converted, customary, Delta, depository, discretion, EC, ejection, environmental, equal, ethical, expanded, expiration, fail, fully, Goldman, greater, HFrEF, HRD, IASB, Ib, IIIa, Immunology, indirect, inoperable, issuable, issuance, JPMorgan, Koselugo, loan, Lokelma, mandatory, merge, Merger, minimum, Morgan, NA, Nasdaq, older, Omega, outpatient, paediatric, pandemic, par, partnership, pen, peptidase, plexiform, premium, prostate, quorum, refinanced, repayment, Ryotanki, satisfied, simultaneously, solid, Stanley, substantially, successfully, Superior, symptomatic, syndicated, typical, utilization, VBP, waiting, wholly
Removed:
AB, alleging, aware, branded, Canada, certify, complaint, complied, composed, conflicting, consisted, constitute, continue, disclosure, District, exclusivity, expense, fixed, generated, great, higher, inventory, licence, mix, MSD, noted, notify, NYSE, orphan, Pharma, platform, pressure, progressed, reflected, registrar, return, revision, statutory, supplement, sustainability, Swedish, thereto, unqualified, violation, writing, XR, York
Financial reports
20-F
2020 FY
Annual report (foreign)
15 Feb 21
20-F
2019 FY
Annual report (foreign)
2 Mar 20
20-F
2018 FY
Annual report (foreign)
4 Mar 19
20-F
2017 FY
Annual report (foreign)
5 Mar 18
20-F
2016 FY
Annual report (foreign)
6 Mar 17
20-F
2015 FY
Annual report (foreign)
7 Mar 16
20-F
2014 FY
Annual report (foreign)
9 Mar 15
20-F
2013 FY
Annual report (foreign)
19 Mar 14
20-F
2012 FY
Annual report (foreign)
24 Mar 13
20-F/A
2011 FY
Annual report (foreign) (amended)
20 Sep 12
Current reports
6-K
Total Voting Rights
2 Aug 21
6-K
Saphnelo Approved In the Us for Sle
2 Aug 21
6-K/A
2021 Q2
Current report (foreign) (amended)
30 Jul 21
6-K
2021 Q2
Current report (foreign)
29 Jul 21
6-K
Ultomiris Recommended In Eu for Children with PNH
26 Jul 21
6-K
Directorate Change
22 Jul 21
6-K
Current report (foreign)
21 Jul 21
6-K
Director/pdmr Shareholding
21 Jul 21
6-K
Total Voting Rights
21 Jul 21
6-K
Acquisition of Alexion Completed
21 Jul 21
Registration and prospectus
F-6EF
Automatic registration for ADRs (foreign)
19 Jul 21
425
Business combination disclosure
14 Jul 21
425
Business combination disclosure
14 Jul 21
425
Business combination disclosure
6 Jul 21
425
Business combination disclosure
6 Jul 21
425
Business combination disclosure
30 Jun 21
425
Business combination disclosure
4 Jun 21
425
Business combination disclosure
4 Jun 21
8-A12B
Registration of securities on exchange
1 Jun 21
424B2
Prospectus for primary offering
27 May 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
7 Apr 21
UPLOAD
Letter from SEC
28 Feb 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
16 Feb 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
3 Mar 20
EFFECT
Notice of effectiveness
7 Feb 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 18
CERTNYS
Certification of approval for NYSE listing
13 Jun 17
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
7 Mar 17
Ownership
SC 13G
Aridis Pharmaceuticals / ASTRAZENECA ownership change
27 Jul 21
11-K
Annual report of employee stock purchases
29 Jun 21
SC 13G
PIERIS PHARMACEUTICALS / ASTRAZENECA ownership change
7 Apr 21
4
Change in insider ownership
16 Mar 21
SC 13G
ADC Therapeutics / ASTRAZENECA ownership change
10 Feb 21
SC 13G/A
Moderna / ASTRAZENECA ownership change
10 Feb 21
SC 13G/A
ASTRAZENECA / WELLINGTON MANAGEMENT ownership change
3 Feb 21
SC 13G/A
ASTRAZENECA / BlackRock ownership change
28 Jan 21
4
Change in insider ownership
7 Feb 20
3
Initial statement of insider ownership
7 Feb 20
Reddit threads
I scanned over 150 charts this weekend. Here are some good setups I found to BTD (or sell CSPs): SKLZ, PTON, FUBO, TDOC, AAL, MU
1 Aug 21
If you could only own 1 dividend stock, what would it be?
1 Aug 21
Most Anticipated Earnings Releases for the week beginning August 2nd, 2021
31 Jul 21
Stock Watch List July 29, 2021
29 Jul 21
Daily Discussion Thread - July 29th, 2021
29 Jul 21
Daily Discussion Thread - July 28th, 2021
28 Jul 21
Daily Discussion Thread - July 27th, 2021
27 Jul 21
Daily Discussion Thread - July 26th, 2021
26 Jul 21
Most anticipated earnings releases for the week beginning July 26, 2021
24 Jul 21
How did AZN end up in my Robinhood portfolio? I had never heard of it and it just ended up there!
22 Jul 21